Company news
Beijing Foyou Pharma Co., Ltd. Class A (SSE:601089) news
Beijing Foyou Pharma Co., Ltd. Class A news releases on 6ix. Latest, Jul 5, 2025: Announcement on Obtaining Drug Registration Certificate for Amorolfine…
Press releases — page 2
Announcement on Obtaining Drug Registration Certificate for Amorolfine Hydrochloride Liniment
July 4, 2025
Announcement on Obtaining Drug Registration Certificate for Benidipine Hydrochloride Tablets
July 1, 2025
Announcement on Listing and Circulation of Restricted Shares in Initial Public Offering
June 24, 2025
Announcement on Obtaining Drug Registration Certificate for Acipimox Capsules
June 10, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of Ketoprofen Patch
June 5, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of Lidocaine Prilocaine Cutaneous Spray Solution
May 29, 2025
Announcement on the Completion of Term Change and Election of Board of Directors and Board of Supervisors and Appointment of Senior Management Members, Head of Audit Department and Securities Affairs Representative
May 28, 2025
Announcement on Resolution of the 1st Extraordinary General Meeting in 2025
May 27, 2025
Announcement on Resolutions of the 17th Meeting of the 2nd Board of Directors
April 29, 2025
Announcement on Resolutions of the 2024 Annual General Meeting
April 28, 2025
Announcement on Obtaining Drug Registration Certificate for Rosuvastatin Calcium and Ezetimibe Tablets (I)
April 25, 2025
Announcement on Convening the Q1 2025 Performance Briefing
April 24, 2025